SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 407.32 |
| Enterprise Value ($M) | 281.75 |
| Book Value ($M) | 205.46 |
| Book Value / Share | 3.34 |
| Price / Book | 1.98 |
| NCAV ($M) | 141.58 |
| NCAV / Share | 2.30 |
| Price / NCAV | 2.88 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.48 |
| Return on Assets (ROA) | -0.39 |
| Return on Equity (ROE) | -0.67 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.03 |
| Current Ratio | 6.03 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 251.21 |
| Assets | 315.08 |
| Liabilities | 109.62 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Avoro Capital Advisors LLC | |||
| 13G | BlackRock, Inc. | |||
| 13G | Biotechnology Value Fund L P | |||
| 13G | Vanguard Group Inc | |||
| 13G/A | Price T Rowe Associates Inc /md/ | 10.80 | 29.52 | |
| 13G/A | Fmr Llc | 8.31 | -7.87 | |
| 13D/A | Versant Venture Capital VI, L.P. | 6.60 | -20.00 | |
| 13D/A | New Enterprise Associates 17, L.P. | 12.70 | -0.13 | |
| 13G/A | Cormorant Asset Management, LP | 0.00 | -100.00 | |
| 13G | Baker Bros. Advisors Lp | 9.80 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 118,856 | 522,864 | 22.73 | |
| 129,519 | 437,076 | 29.63 | |
| 126,919 | 396,402 | 32.02 | |
| 136,601 | 439,090 | 31.11 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GBIO – Generation Bio Co. | GERN – Geron Corporation |
| GILD – Gilead Sciences, Inc. | GOSS – Gossamer Bio, Inc. |
| HALO – Halozyme Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io